{"id":{"repo_id":"strathclyde","oai_identifier":"oai:strathclyde:sb397828k"},"canonical_url":"https://search.dev.ndltd.org/etd/strathclyde/oai:strathclyde:sb397828k","repository":{"repo_id":"strathclyde","name":"University of Strathclyde","base_url":"https://stax.strath.ac.uk/catalog/oai"},"display":{"title":"The design and characterisation of multiparticulate lipidic systems for oral drug delivery","abstract":"The aim of the current research was to develop a sustained release hydrophobic matrix drug delivery system utilising extrusion spheronisation. The initial formulation supplied was Sebomin® MR 100mg capsules, an oral modified release commercial product. A technological transfer was undertaken to reproduce the Sebomin® multiparticulate product utilising lab-scale extrusion/spheronisation equipment. On successful completion, modulation of various processing parameters and the effect on the resultant granule and pellet characteristics evaluated. The potential to develop a sustained release wax matrix formulation via the current technology was unsuccessful and led to the development of a hot-melt spray system. To characterise and validate the hot-melt spray system, OFAT and experimental design approaches were utilised. The process proved to be robust and reproducible in the production of sprayed wax granules. A stability study of the sprayed glyceryl monostearate (GMS) granules indicated the production of the unstable α-form of GMS, during storage the GMS reverted into the stable β-form. Incorporation of active pharmaceutical ingredients and additional excipients into the sprayed wax matrix system enabled in-vitro properties to be evaluated from both sprayed solid solutions and solid dispersions. Screening techniques including differential scanning calorimetry, FT-IR, hot-stage microscopy, X-ray powder diffraction, scanning electron microscopy and dissolution testing were successfully employed to identify changes to the physicochemical properties of materials that may impact product performance.","abstract_html":"The aim of the current research was to develop a sustained release hydrophobic matrix drug delivery system utilising extrusion spheronisation. The initial formulation supplied was Sebomin® MR 100mg capsules, an oral modified release commercial product. A technological transfer was undertaken to reproduce the Sebomin® multiparticulate product utilising lab-scale extrusion/spheronisation equipment. On successful completion, modulation of various processing parameters and the effect on the resultant granule and pellet characteristics evaluated. The potential to develop a sustained release wax matrix formulation via the current technology was unsuccessful and led to the development of a hot-melt spray system. To characterise and validate the hot-melt spray system, OFAT and experimental design approaches were utilised. The process proved to be robust and reproducible in the production of sprayed wax granules. A stability study of the sprayed glyceryl monostearate (GMS) granules indicated the production of the unstable α-form of GMS, during storage the GMS reverted into the stable β-form. Incorporation of active pharmaceutical ingredients and additional excipients into the sprayed wax matrix system enabled in-vitro properties to be evaluated from both sprayed solid solutions and solid dispersions. Screening techniques including differential scanning calorimetry, FT-IR, hot-stage microscopy, X-ray powder diffraction, scanning electron microscopy and dissolution testing were successfully employed to identify changes to the physicochemical properties of materials that may impact product performance.","abstract_has_math":false,"creators":["Coombs, Gemma"],"institution":"University of Strathclyde","degree_name":"phd","degree_level":"doctoral-pg","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013","date_published":"2013","updated_at":"2026-07-24T04:51:37Z","subjects":[],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.doi","label":"DOI","values":["10.48730/7kem-df95"],"render_values":[{"text":"10.48730/7kem-df95","href":"https://doi.org/10.48730/7kem-df95","code":true}]},{"key":"dc:identifier","label":"Identifier","values":["T13429"],"render_values":[{"text":"T13429","href":null,"code":true}]}]},"links":{"outbound_url":"https://stax.strath.ac.uk/concern/theses/sb397828k","outbound_label":"Repository record","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Coombs, Gemma"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2013"]},{"key":"dc:date.issued","label":"Date","values":["2013"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["Strathclyde Institute of Pharmacy and Biomedical Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Strathclyde"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["doctoral-pg"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["phd"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["T13429"]},{"key":"dc:identifier.doi","label":"DOI","values":["10.48730/7kem-df95"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://stax.strath.ac.uk/concern/theses/sb397828k"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Strathclyde theses - ask staff. Thesis no. : T13429","The aim of the current research was to develop a sustained release hydrophobic matrix drug delivery system utilising extrusion spheronisation. The initial formulation supplied was Sebomin® MR 100mg capsules, an oral modified release commercial product. A technological transfer was undertaken to reproduce the Sebomin® multiparticulate product utilising lab-scale extrusion/spheronisation equipment. On successful completion, modulation of various processing parameters and the effect on the resultant granule and pellet characteristics evaluated. The potential to develop a sustained release wax matrix formulation via the current technology was unsuccessful and led to the development of a hot-melt spray system. To characterise and validate the hot-melt spray system, OFAT and experimental design approaches were utilised. The process proved to be robust and reproducible in the production of sprayed wax granules. A stability study of the sprayed glyceryl monostearate (GMS) granules indicated the production of the unstable α-form of GMS, during storage the GMS reverted into the stable β-form. Incorporation of active pharmaceutical ingredients and additional excipients into the sprayed wax matrix system enabled in-vitro properties to be evaluated from both sprayed solid solutions and solid dispersions. Screening techniques including differential scanning calorimetry, FT-IR, hot-stage microscopy, X-ray powder diffraction, scanning electron microscopy and dissolution testing were successfully employed to identify changes to the physicochemical properties of materials that may impact product performance."]},{"key":"dc:description.abstract","label":"Abstract","values":["The aim of the current research was to develop a sustained release hydrophobic matrix drug delivery system utilising extrusion spheronisation. The initial formulation supplied was Sebomin® MR 100mg capsules, an oral modified release commercial product. A technological transfer was undertaken to reproduce the Sebomin® multiparticulate product utilising lab-scale extrusion/spheronisation equipment. On successful completion, modulation of various processing parameters and the effect on the resultant granule and pellet characteristics evaluated. The potential to develop a sustained release wax matrix formulation via the current technology was unsuccessful and led to the development of a hot-melt spray system. To characterise and validate the hot-melt spray system, OFAT and experimental design approaches were utilised. The process proved to be robust and reproducible in the production of sprayed wax granules. A stability study of the sprayed glyceryl monostearate (GMS) granules indicated the production of the unstable α-form of GMS, during storage the GMS reverted into the stable β-form. Incorporation of active pharmaceutical ingredients and additional excipients into the sprayed wax matrix system enabled in-vitro properties to be evaluated from both sprayed solid solutions and solid dispersions. Screening techniques including differential scanning calorimetry, FT-IR, hot-stage microscopy, X-ray powder diffraction, scanning electron microscopy and dissolution testing were successfully employed to identify changes to the physicochemical properties of materials that may impact product performance."]},{"key":"dc:title","label":"Title","values":["The design and characterisation of multiparticulate lipidic systems for oral drug delivery"]}]}],"canonical_facts":{"dc:creator":["Coombs, Gemma"],"dc:date":["2013"],"dc:date.issued":["2013"],"dc:description":["Strathclyde theses - ask staff. Thesis no. : T13429","The aim of the current research was to develop a sustained release hydrophobic matrix drug delivery system utilising extrusion spheronisation. The initial formulation supplied was Sebomin® MR 100mg capsules, an oral modified release commercial product. A technological transfer was undertaken to reproduce the Sebomin® multiparticulate product utilising lab-scale extrusion/spheronisation equipment. On successful completion, modulation of various processing parameters and the effect on the resultant granule and pellet characteristics evaluated. The potential to develop a sustained release wax matrix formulation via the current technology was unsuccessful and led to the development of a hot-melt spray system. To characterise and validate the hot-melt spray system, OFAT and experimental design approaches were utilised. The process proved to be robust and reproducible in the production of sprayed wax granules. A stability study of the sprayed glyceryl monostearate (GMS) granules indicated the production of the unstable α-form of GMS, during storage the GMS reverted into the stable β-form. Incorporation of active pharmaceutical ingredients and additional excipients into the sprayed wax matrix system enabled in-vitro properties to be evaluated from both sprayed solid solutions and solid dispersions. Screening techniques including differential scanning calorimetry, FT-IR, hot-stage microscopy, X-ray powder diffraction, scanning electron microscopy and dissolution testing were successfully employed to identify changes to the physicochemical properties of materials that may impact product performance."],"dc:description.abstract":["The aim of the current research was to develop a sustained release hydrophobic matrix drug delivery system utilising extrusion spheronisation. The initial formulation supplied was Sebomin® MR 100mg capsules, an oral modified release commercial product. A technological transfer was undertaken to reproduce the Sebomin® multiparticulate product utilising lab-scale extrusion/spheronisation equipment. On successful completion, modulation of various processing parameters and the effect on the resultant granule and pellet characteristics evaluated. The potential to develop a sustained release wax matrix formulation via the current technology was unsuccessful and led to the development of a hot-melt spray system. To characterise and validate the hot-melt spray system, OFAT and experimental design approaches were utilised. The process proved to be robust and reproducible in the production of sprayed wax granules. A stability study of the sprayed glyceryl monostearate (GMS) granules indicated the production of the unstable α-form of GMS, during storage the GMS reverted into the stable β-form. Incorporation of active pharmaceutical ingredients and additional excipients into the sprayed wax matrix system enabled in-vitro properties to be evaluated from both sprayed solid solutions and solid dispersions. Screening techniques including differential scanning calorimetry, FT-IR, hot-stage microscopy, X-ray powder diffraction, scanning electron microscopy and dissolution testing were successfully employed to identify changes to the physicochemical properties of materials that may impact product performance."],"dc:identifier":["T13429"],"dc:identifier.doi":["10.48730/7kem-df95"],"dc:identifier.uri":["https://stax.strath.ac.uk/concern/theses/sb397828k"],"dc:publisher.department":["Strathclyde Institute of Pharmacy and Biomedical Sciences"],"dc:publisher.institution":["University of Strathclyde"],"dc:title":["The design and characterisation of multiparticulate lipidic systems for oral drug delivery"],"dc:type.qualificationlevel":["doctoral-pg"],"dc:type.qualificationname":["phd"]},"updated_at":"2026-07-24T04:51:37Z"}